SciClone Tumbles After Cancer Drug Trial Stops
NEW YORK (AP) ¿ Shares of SciClone Pharmaceuticals Inc. dropped Monday after the company suspended a study of its drug candidate RP101, which was intended as a treatment for late stage pancreatic cancer.
On Friday, SciClone said a data monitoring committee recommended it stop the trial. The company has not yet seen full results from the midstage study. In heavy afternoon trading, SciClone shares fell 67 cents, or 16.1 percent, to $3.48.
Despite the end of the trial, Rodman & Renshaw analyst Reni Benjamin kept a "Market Outperform" rating on SciClone. Benjamin said the company has a strong pipeline, and said he expects strong sales of SciClone's drug Zadaxin.
Zadaxin is used to treat hepatitis B and C, and is used to increase the effectiveness of some vaccines. It has not been approved in the U.S. Sales totaled $54.1 million in 2008, and Benjamin expects that to rise to about $73 million this year.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV